In intestinal allografts, endoscopy and histology detect the injury once changes in the bowel wall architecture have occurred. We aimed to identify a molecular signature that could predict early deterioration, within histologically indistinguishable biopsies with "minimal changes" (MC) pathology. Sixty biopsies from 12 adult recipients were longitudinally taken during 8 years post-transplant. They were classified as either stable (STA) or non-stable (NSTA) according to the prospectively recorded number, frequency and severity of rejection events of the allograft. In a discovery set of MC samples analyzed by RNA-Seq, 816 genes were differentially expressed in STA vs NSTA biopsies. A group of 5 genes (ADH1C, SLC39A4, CYP4F2, OPTN and PDZK1) correctly classified all NSTA biopsies in the discovery set and all STA biopsies from an independent set. These results were validated by qPCR in a new group of MC biopsies.
Introduction
Intestinal transplantation (IT) is a procedure to treat irreversible intestinal failure (caused in most cases by a short bowel syndrome) in patients suffering life-threatening complications of parenteral nutrition. Until 2014, nearly 2500 ITx cases had been performed throughout the world, but despite recent improvements, management of IT recipients is still challenging (Grant et al., 2015; Kubal et al., 2015; Smith et al., 2017; Sudan, 2014) . In contrast to other organs, the transplanted small bowel bears an important proportion of immune cells and commensal bacterial flora, making it prone to inflammation and infection. The acute rejection rate of intestinal allografts is higher than in other organs and may appear early after transplantation and repeatedly with time (Ruiz, 2012) . Severe rejection episodes involve immune mechanisms that eventually damage the intestinal absorptive capacity and favor the translocation of luminal bacteria, which are closely associated with graft loss and patient death. Other posttransplant (post-Tx) events such as lymphoproliferative disease, graft versus host disease, ulcers, enteritis, eosinophilic syndromes or de novo autoimmunity, derive from a complex interplay of both non-immune and immune factors as yet barely understood (Fishbein, 2009; Kroemer et al., 2016; Loo et al., 2017; Ranganathan et al., 2015; Selvaggi et al., 2007) .
Monitoring of IT integrity relies on endoscopic and histological examination of intestinal mucosa biopsies, continuously performed during the first post-Tx period. However, in a recent series investigating 1770 endoscopies in pediatric transplants, 45% of biopsyproven rejections showed a normal gross appearance, suggesting a low correlation between endoscopy and histology (Yeh et al., 2015) . Thus, in many cases, these ACCEPTED MANUSCRIPT
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procedures detect the problems once tissular changes have occurred, although the responsible molecular mechanisms may significantly precede them.
In the clinical transplantation arena there is a need for predictive biomarkers for allograft evolution. The transcriptome analysis of the transplanted organ was introduced to identify molecular signatures for rejection, tolerance or drug toxicity. These studies aim to translate into the clinical setting by proposing the measurement of a reduced number of differentially expressed genes to anticipate the event and guide therapy. However, most studies show two important limitations. Firstly, because they analyze very selected and distant pathology phenotypes, i.e. normal vs acute rejection biopsies, their results do not provide additional information to that already known. Secondly, in all cases gene expression is measured with probe arrays which do not interrogate the whole transcriptome but an a priori determined set of transcripts.
In the present work, we aim to identify a molecular signature of IT deterioration before it translates into visible histological injuries. We explored histologically indistinguishable IT biopsies with minimal changes (MC), which corresponded to either stable (STA) or nonstable (NSTA) intestinal transplants. Because of its potential to quantify the complete transcriptome we used massive RNA sequencing (RNA-Seq) to measure differently expressed genes (Marguerat and Bahler, 2010; Wang et al., 2009) . With the unprecedented use of this tool for biomarker discovery in transplantation, we identified and validated a 5-gene set as a molecular classifier with a good predictive capacity for the evolution of IT. The measurement of these 5 genes in IT biopsies by quantitative PCR (qPCR) may identify unstable intestinal allografts and guide early therapeutic intervention.
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Materials and Methods
Patients, biopsies and study design
The study included 12 adult recipients who had undergone small bowel (SBT) or multivisceral transplantation between 2005 and 2015 in our hospital (Table 1) . Biopsies from ileal mucosa were taken at 10-20 cm from ileostomy. Endoscopic and biopsy controls were performed soon after transplantation and at progressively increasing intervals (2 per week during 1 st month, 1 per week during 2 nd and 3 rd months, 1 every two weeks during 4 th and 5 th months, 1 monthly until the end of the first year, and then once every six months). According to this protocol, biopsies were routinely taken even in the absence of clinical symptoms, and additional endoscopies and biopsies were performed when clinical events appeared. Data from histological diagnosis from paired biopsies (examined by at least two independent pathologists) and immunosuppressive therapy were also collected. MC were considered in biopsies without specific histopathologic changes, closely resembling the features of normal gut. Indeterminate for rejection (IRX) was considered in biopsies with minimal rejection, less than 6 apoptosis in 10 crypts, mild inflammatory infiltrate and edema. Rejection grade 1 (RX) was defined by increased apoptosis in crypts and epithelium, occasional endothelitis and mild villous blunting ( Figure S1 ) (Andreev et al., 2011; Wu et al., 2003) .
All patients received alemtuzumab for induction therapy, except P11 (SBT plus kidney recipient) and P12 who received thymoglobulin. The main immunosuppressive drug was tacrolimus in all patients. Mycophenolate mofetil was added in patients P1, P2, P3, P4
and P12 within the first three months post-Tx. P4, P6, P10, P11 and P12 received
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Corticosteroids were administered because of a rejection episode in P3, P4, P7, P8, P10 and P11 and because of Crohn's disease (P5), adrenal insufficiency (P10) or kidney allograft (P11).
A total of 60 IT biopsies were longitudinally taken between 2011 and 2015 in a post-Tx period of 13 to 3101 days. Fifty biopsies showed MC, 7 were IRX, and 3 showed RX ( Figure 1A shows the workflow for biomarker identification and validation. Twenty-four MC samples (discovery and test sets, 17 STA and 7 NSTA) from 8 patients ( Figure 1B and Table 2 ) were analyzed by RNA-Seq. Eighteen biopsies for the discovery set (11 STA and 7 NSTA) were obtained from 4 IT recipients. To minimize differences due to
A C C E P T E D M A N U S C R I P T the intrinsic characteristics of patients, 3 recipients (P2, P3 and P4) were included because they were the only ones with both STA and NSTA biopsies. All biopsies from the fourth patient included in the discovery set (P1) were STA samples, but they were obtained at a post-Tx period matching that of the other 3 recipients (most biopsies taken within the first year post-Tx) ( Figure 1B ). The other 6 biopsies from the remaining 4 patients (P5, P6, P7 and P8) were used as the test set. These 6 biopsies were all STA and were taken at long post-Tx time (more than two years) ( Figure 1B and Table 2 ).
Genes obtained in the RNA-Seq stage as possible biomarkers were validated as predictors by qPCR and logistic regression in a validation set formed by 26 independent biopsies (17 STA and 9 NSTA) from 9 patients. The model was then tested in a rejection set formed by 10 new biopsies (7 IRX and 3 RX) from 4 patients, and in 16 biopsies from the initial discovery set ( Figure 1 and Table 2 ).
Experiments were approved by the institutional review board (CEIC 13/370) and written informed consent was obtained from all patients.
RNA isolation and quality control
Following extraction, intestinal biopsies were immediately submerged in RNAlater solution (Ambion, Austin, TX, USA) and stored at -80ºC. Samples were maintained this way until RNA extraction, which was performed just before sample processing. After tissue disruption with needle and syringe and homogenization with QIAshredder, RNA was isolated and purified with RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA integrity of samples included in RNA-Seq (24) 
RNA-Seq data analysis and classifier discovery
Sequencing adapter contaminations and low-quality reads were removed using Cutadapt software v1.6 (Martin, 2011). Resulting reads were aligned to the reference human genome (Ensembl gene-build GRCh37.75) using TopHat2 v2.0.13 (Kim et al., 2013; Trapnell et al., 2012) . Gene expression values were calculated as counts using HTSeq v0.6.1 (Anders et al., 2015) . Only genes above 1 count per million (cpm) in all samples were considered for statistical analysis. Data were then normalized by trimmed mean of M-values normalization method (TMM) and differences between STA and NSTA groups in the discovery set were tested by a generalized linear model (GLM)
analysis. To reduce error variance, patient identity and treatment with or without corticosteroids were incorporated into the linear predictor model as blocking factors, so their effects could be discarded when comparing biopsies. Both normalization and model fitting were implemented with the R Bioconductor package edgeR (Robinson et al., 2010) . Results were considered significant when Benjamini-Hochberg adjusted pvalue was < 0,05 (false discovery rate, FDR<5%). Gene classification, training and testing were performed using nearest shrunken centroids (NSC) method with the R Bioconductor package pamr (Hibi et al., 2012; Tibshirani et al., 2002) and support vector machine (SVM), bagSVM and random forest (RF) (Chen and Ishwaran, 2012; Furey et al., 2000; Peng, 2006; Wang and Sarwal, 2015) with the R Bioconductor package MLSeq. BioGPS (Su et al., 2004; Wu et al., 2009 ) was used to assess the biological significance of the selected genes. A gene was considered tissue-specific if its expression was at least 3-fold higher in a given tissue than the median expression of the gene across all tissues (Khatri et al., 2013; Roedder et al., 2015) .
Quantitative real-time Polymerase Chain Reaction (qPCR)
The expression of the 5 genes selected as classifiers (ADH1C, SLC39A4, CYP4F2, (Schmittgen and Livak, 2008) . To evaluate the performance of the classifiers as a diagnosis test, a logistic regression model with Firth penalization (used to reduce small-sample bias in maximum likelihood estimation) (Firth, 1993; Heinze and Puhr, 2010; Markowetz and Spang, 2005; Wang, 2014) was built with the relative gene expression data of the validation set. Bootstrap operations for confidence interval (CI) were performed with a non-parametric non-stratified resampling and with the percentile method, as previously described (Carpenter and Bithell, 2000 ). The generated model was then validated in the rejection set and also in 16 samples of the discovery set. R Bioconductor packages logistf (Heinze et al., 2013) , pROC (Robin et al., 2011) and Epi (Carstensen et al., 2017) were used for statistical computing.
Data from qPCR and all R scripts are available as Supplementary Materials and Methods in the Mendeley Data Repository. Tables 1 and 2 summarize the main characteristics of IT recipients and collected biopsies. Figure 1 shows the flowchart and composition of every sample set analyzed.
Results
genes are differentially expressed in stable and non-stable biopsies
MC biopsies ( Figure S1 ) were classified into STA or NSTA samples according to criteria described in the Materials and Methods section. By analyzing the data obtained from the RNA-Seq of the discovery set we aimed to find differentially expressed genes (DEGs) between STA and NSTA biopsies in spite of all them being MC, histologically Figure S2A ). Because the MDS plot showed a bias by patient identification, this was considered as a blocking factor in GLM analysis when computing differential expression. Administration of corticosteroids at the time of collecting the biopsy was also taken into account as a blocking factor, since it is directly related to rejection. We found 816 DEGs between STA and NSTA biopsies (FDR < 5%); 369 of them were downregulated and 447 were upregulated in NSTA group ( Figure S2B ).
classifier genes discriminate STA and NSTA biopsies
To find a gene signature that could discriminate between STA and NSTA biopsies we performed a NSC analysis with the 816 DEGs. A subset of 5 DEGs was obtained:
ADH1C (class I alcohol dehydrogenase gamma subunit), SLC39A4 (solute carrier family 39, member 4), CYP4F2 (cytochrome P450, family 4, subfamily F, polypeptide 2), OPTN (optineurin) and PDZK1 (sodium-hydrogen exchanger regulatory factor 3).
ADH1C was more expressed and SLC39A4, CYP4F2, OPTN and PDZK1 were downregulated in NSTA biopsies (Figure 2A ). These 5 genes classified biopsies of the discovery set in STA and NSTA with an overall error rate of 11%, showing a misclassification of 2 out of 11 STA biopsies as NSTA ( Figure 2B and Table S1) whereas, importantly, all NSTA biopsies were correctly classified. When we calculated the probability of being NSTA in the test set (formed by 6 STA samples) with the model built by the NSC method, all biopsies were correctly classified as STA with NSTA
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regression coefficients that describe the size of the contribution of each gene as a risk factor.
Based on the ROC curve built upon this regression model with an AUC of 0.81 (95% CI, 0.63 to 0.96), a cutoff value θ=0.28 classified NSTA and STA samples with 53% specificity and the highest sensitivity (100%) (95% CI, 0.29 to 0.76), and, importantly, it allowed the detection of every NSTA biopsy ( Figure 4A ). The 5 gene-model was subsequently tested in a set of samples with histological diagnosis of IRX (n=7) or acute rejection (n=3, Table 2 ), under the hypothesis that it should classify these samples as NSTA. Assuming the same reference value of 0.28 as a classifier score, the model misclassified only one IRX sample and one RX biopsy (the last one with a predicted probability of 0.27) ( Figure 4B ). Finally, within 16 biopsies from discovery set (9 STA and 7 NSTA) tested by the regression model, only two NSTA samples were misclassified ( Figure 4C ). Taking together all the results obtained in the three sets of samples (discovery, rejection and validation), the model showed an accuracy of 77% (85% sensitivity, 69% specificity, 73% positive predictive value, 82% negative predictive value). Figure 4D shows the predicted probabilities in four different patients, those with a higher number of studied biopsies along post-Tx time. Patient 1 never suffered rejection so, with regard to our initial definition, all his 6 biopsies were STA. According to predicted probabilities, only the sample obtained at day 26 post-Tx was misclassified, whereas all other biopsies (from day 33 to 1201 post-Tx) were correctly classified. Within 12 samples from patient 2, only two were misclassified. The first was a RX biopsy taken at day 58 and was classified as STA with a probability value very close to the cutoff (0.27).
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The second misclassified biopsy was taken on day 448. This sample, which was diagnosed as IRX, was an isolated biopsy with no previous or later RX or IRX biopsies.
The patient did not develop clinical symptoms of rejection and no changes were made in the immunosuppression. Accordingly, this biopsy might well have been classified as MC and STA. Patient 4 suffered several IRX biopsies and many rejection episodes even two years post-Tx. The unstable evolution of his intestinal graft is well reflected by the predicted probabilities that show three misclassifications (within 11 samples analyzed).
Patient 12 showed only one misclassification out of 11 samples, corresponding to the biopsy obtained at day 171 (STA). Although this sample was classified as NSTA, its predicted probability was lower than probabilities for the same patient NSTA, RX or IRX biopsies. These examples illustrate that the molecular signature described here may be more accurate than histology to diagnose the status of intestinal allograft. Not only the predicted probability values of isolated samples, but also the trend of probabilities within each patient could be a guide to prognosticate the transplant stability.
Discussion
The design of the present analysis shows three main strengths. We performed a search of the 5 genes reported here across all transplantation-related transcriptomes deposited in GEO. In a study of renal transplants, all 5 genes were more expressed in biopsies from well-functioning grafts than in biopsies from acute rejection or renal dysfunction without rejection (Flechner et al., 2004) . This is consistent with changes in the same direction for CYP4F2, PDZK1, SLC39A4 and OPTN in the present study, as these genes were significantly more expressed in STA vs NSTA samples.
All 5 genes included in the molecular signature are important for the enteric physiology. 
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A N U S C R I P T SLC39A4, also known as ZIP4, is abundantly expressed in the apical membrane of the enterocytes. Mutations in SLC39A4 impair zinc absorption and cause acrodermatitis enteropathica (Kury et al., 2002; Ye ruva et al., 2015) . Insufficient zinc absorption is commonly observed among IT recipients (Ubesie et al., 2013; Venick et al., 2006; Venick et al., 2011) . Overexpression of SLC39A4 in hepatocellular or pancreatic carcinomas increases cell growth and represses apoptosis (Weaver et al., 2010; Zhang et al., 2010) , while its lack in enterocytic-specific SLC39A4 KO mice causes dysfunction of Paneth cells that leads to disruption of the villus stem cell niche in the crypts.
Remarkably, apoptosis and crypts distortion are hallmarks of intestinal allograft rejection (Ruiz et al., 2004; Ruiz et al., 2010) .
Within the 5-gene signature, only OPTN is significantly expressed in lymphoid cells.
This is biologically consistent with the fact that the inflammatory infiltrate was not a prominent feature in most samples, as they were MC biopsies. Optineurin participates in the autophagy process to limit intracellular proliferation of Salmonella (Wild et al., 2011) .
Mice without OPTN are significantly susceptible to Salmonella infection (Slowicka et al., 2016) and peritonitis caused by Citrobacter colitis and E. coli, due to reduced neutrophil recruitment to sites of acute inflammation and impaired pro-inflammatory cytokine secretion. (Chew et al., 2015) . In a subgroup of patients with Crohn's disease, optineurin was the most common under-expressed transcript in macrophages, which were also defective in production and release of tumor necrosis factor and interferon-γ after stimulation by E. coli (Smith et al., 2015) . Interestingly, profiling of microbiota in ileal effluents from transplanted intestines showed an increase of taxa from the Enterobacteriaceae family during rejection (Oh et al., 2012) . These data suggest a role Histological findings of intestinal rejection (Ruiz et al., 2004) are not specific and high apoptosis rates can be found in patients receiving mycophenolate mofetil (Apostolov et al., 2017) or during adenovirus infections (Kaufman et al., 2002) . As the 5-gene set also identifies RX and IRX biopsies, it could be useful to discriminate those "false rejection"
biopsies, avoiding the aggressive anti-rejection therapies. Larger studies of more samples, pediatric patients and a prospective and multicenter design may provide further evidence of our results and confirm their clinical usefulness.
A N U S C R I P T Numbers between ( ) represent days post-transplantation / Bx: biopsies / STA: biopsy with minimal changes considered in the stable group / NSTA: biopsy with minimal changes considered in the non-stable group / IRX: biopsy with a diagnosis of indeterminated for rejection / RX: biopsy with a diagnosis of acute rejection grade 1.
A N U S C R I P T Table 3 . Results of prediction by SVM, bagSVM and RF methods. 
Method
